

## Personal Information

Email: gozdekavgaci@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/gozdekavgaci>

## International Researcher IDs

ORCID: 0000-0001-6960-2024

Yoksis Researcher ID: 132239

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Ribociclib-induced autoimmune-like hepatitis: a case report**  
KAVGACI G., ŞAHİN T. K., SÖKMENSÜER C., BALABAN H. Y., AKSOY S.  
JOURNAL OF CHEMOTHERAPY, 2024 (SCI-Expanded)
- II. **The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer**  
YILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., Chalabiyev E., Yilmaz F., Yildirim S. S., KUŞ F., et al.  
MEDICINE, no.30, 2024 (SCI-Expanded)
- III. **Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine**  
ŞAHİN T. K., AKYILDIZ A., DOĞAN O. T., KAVGACI G., GÜVEN D. C., AKSOY S.  
PHARMACEUTICALS, no.7, 2024 (SCI-Expanded)
- IV. **Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors**  
KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., AKSOY S., ERMAN M., YALÇIN Ş.  
SUPPORTIVE CARE IN CANCER, no.7, 2024 (SCI-Expanded)
- V. **Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer**  
KAVGACI G., Dizdar O., Yalcin S.  
Anti-cancer drugs, vol.35, no.5, pp.459-461, 2024 (SCI-Expanded)
- VI. **Acute heart failure following pazopanib treatment: a literature review featuring two case reports**  
KERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.  
Anti-Cancer Drugs, vol.35, no.3, pp.302-304, 2024 (SCI-Expanded)
- VII. **The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review**  
GÜVEN D. C., KAVGACI G., ERUL E., Syed M. P., Magge T., Saeed A., YALÇIN Ş., Sahin I. H.  
ONCOLOGIST, 2024 (SCI-Expanded)
- VIII. **Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study**  
YILDIRIM H. Ç., Kapar C., KÖKSAL B., Seyyar M., Sancı P. C., Guliyev M., Perkin P., Buyukkor M., YASLIKAYA Ş., Majidova N., et al.  
Journal of Chemotherapy, 2024 (SCI-Expanded)
- IX. **Advances in the Early Detection of Hepatobiliary Cancers**  
YILDIRIM H. Ç., KAVGACI G., Chalabiyev E., DİZDAR Ö.  
Cancers, vol.15, no.15, 2023 (SCI-Expanded)

- X. **The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors**  
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., YILDIRIM H. Ç., Chalabiyev E., Cebroyilov C., YILDIRIM T., et al.  
Anti-Cancer Drugs, vol.34, no.6, pp.783-790, 2023 (SCI-Expanded)
- XI. **The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy**  
GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., ERMAN M., KILIÇKAP S., YALÇIN Ş.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.4, pp.785-793, 2022 (SCI-Expanded)
- XII. **THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY**  
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebayilov C., YILDIRIM T., DİZDAR Ö., AKSOY S., KILIÇKAP S., et al.  
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.36, 2021 (SCI-Expanded)
- XIII. **Implementation of clinical pharmacy practices in nephrology unit**  
Tecen K., ÜZERK KİBAR M., KAVGACI G., Bayraktar-Ekincioglu A., Demirkan K., YILDIRIM T., YILMAZ Ş. R., ERDEM Y.  
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, vol.40, no.1, pp.281, 2018 (SCI-Expanded)

### Articles Published in Other Journals

- I. **Bilateral Testicular Plasmacytoma Preceding Multiple Myeloma with Extramedullary Renal Involvement: A Case Report**  
KAVGACI G., KÖKSAL B., ARIK Z., BARIŞTA İ., AKIN S.  
PLASMATOLOGY, 2024 (ESCI)
- II. **Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy**  
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., KUŞ F., AKYILDIZ A., GÜRBÜZ S. Ç., Sayin H., et al.  
Journal of Oncological Science, vol.8, no.3, pp.143-147, 2022 (Scopus)

### Refereed Congress / Symposium Publications in Proceedings

- I. **Implementation of clinical pharmacy practices in nephrology unit**  
TECEN YÜCEL K., ÜZERK KİBAR M., KAVGACI G., Ekincioglu A., DEMİRKAN S. K., YILDIRIM T., YILMAZ Ş. R., ERDEM Y.  
46th symposium on clinical pharmacy Heidelberg, Germany, 9 - 11 October 2017

### Metrics

Publication: 16

Citation (Scopus): 3

H-Index (Scopus): 1